<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516681</url>
  </required_header>
  <id_info>
    <org_study_id>Vitamin C-GLUT3-2020</org_study_id>
    <nct_id>NCT04516681</nct_id>
  </id_info>
  <brief_title>IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer</brief_title>
  <official_title>Vitamin C Intravenously With Chemotherapy in Peritoneal Metastatic Colorectal Cancer With High Expresison Level of GLUT3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the&#xD;
      ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the&#xD;
      efficacy of AA. To date, no previous studies have investigated the therapeutic role of AA in&#xD;
      peritoneal metastatic colorectal cancer with high expression of GLUT3. This protocol is a&#xD;
      randomized controlled study of AA infusions combined with FOLFOXIRI +/- bevacizumab versus&#xD;
      treatment with FOLFOXIRI +/- bevacizumab alone in peritoneal metastatic colorectal cancer&#xD;
      patients with high expression of GLUT3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To utilize CT or MRI scans to assess overall tumor response rate (complete and partial response) in subjects with peritoneal metastatic colorectal cancer treated with the combination of ascorbic acid and FOLFOXIRI +/- bevacizumab versus treatment with FOLFOXIRI +/- bevacizumab alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time-to-event outcome measure (initial disease progression) measured in days from cycle 1 day 1 to day of first progression as defined by RECIST1.1 criteria from NCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Time to event outcome measure (death), measured in days from cycle 1 day 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Vitamin C</condition>
  <condition>GLUT3</condition>
  <arm_group>
    <arm_group_label>Combined Ascorbic Acid with chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascorbic Acid with FOLFOXIRI with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy alone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard FOLFOXIRI treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic acid</intervention_name>
    <description>1.5g/kg/day, D1-3, every 2 weeks</description>
    <arm_group_label>Combined Ascorbic Acid with chemotherapy group</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI Protocol</intervention_name>
    <description>CPT-11 165 mg/m² d1 concurrent with Leucovorin 400 mg/m², followed by Oxaliplatin 85 mg/m² d1 followed by Bolus 5FU 400 mg/m² , followed by Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks</description>
    <arm_group_label>Chemotherapy alone group</arm_group_label>
    <arm_group_label>Combined Ascorbic Acid with chemotherapy group</arm_group_label>
    <other_name>FOLFOXIRI+/- bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age≥18 years, ≤75 years; Histologically proven peritoneal metastatic adenocarcinoma of&#xD;
             colorectal cancer, unresectable metastatic disease; IHC confirmed strong positive&#xD;
             GLUT3; measurable disease; Eastern Cooperative Oncology Group (ECOG) performance&#xD;
             status 0 to 1; Life expectancy of at least 12 weeks; ANC ≥1,500/mm3; Hemoglobin &gt;&#xD;
             8g/dL; platelet ≥ 100,000/mm3; Laboratory at baseline evaluation for inclusion in the&#xD;
             study: creatinine ≤1.5X upper limit [if the creatinine is elevated, but ≤1.5X the ULN,&#xD;
             a 24 hour creatinine clearance will be obtained, Creatinine clearance &gt; 50 mL/min&#xD;
             (calculated according to Cockroft and Gault)]; Transaminase (AST/ALT) ≤2.5X upper&#xD;
             limit of normal and bilirubin levels ≤1.5X upper limit of normal without liver&#xD;
             metastasis; Transaminase (AST/ALT) ≤5X upper limit of normal and bilirubin levels&#xD;
             ≤1.5X upper limit of normal with liver metastasis; Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment for metastatic disease (adjuvant therapy with fluoropyrimidines&#xD;
             +/-oxaliplatin based regimens allowed if stopped 12 months prior to registration on&#xD;
             study); Surgery (excluding diagnostic biopsy) or irradiation within 3 weeks prior to&#xD;
             study entry; Administration of any investigational drug or agent/procedure, i.e.&#xD;
             participation in another trial within 4 weeks before beginning treatment; Concurrent&#xD;
             chronic systemic immune therapy, chemotherapy, radiation therapy (palliative radiation&#xD;
             therapy allowed) or hormone therapy not indicated in the study protocol; Brain&#xD;
             metastasis (known or suspected); Pregnant or lactating women; Other uncontrolled&#xD;
             concomitant illness, including serious uncontrolled intercurrent infection; Known&#xD;
             allergy or any other adverse reaction to any of the drugs or to any related compound;&#xD;
             Previous (within 5 years) or concurrent malignancies at other sites with the exception&#xD;
             of surgically cured or adequately treated carcinoma in-situ of the cervix and basal&#xD;
             cell carcinoma of the skin; Patients with low or moderate expression of GLUT3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoxiang Cai, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoxiang Cai</last_name>
    <phone>13122618708</phone>
    <phone_ext>13122618708</phone_ext>
    <email>gxcaifuscc@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Renjie Wang</last_name>
    <phone>18817519285</phone>
    <phone_ext>+86</phone_ext>
    <email>wangbladejay@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan university shanghai cancer center</name>
      <address>
        <city>Shanhai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WEIXING DAI</last_name>
      <phone>13122618708</phone>
      <phone_ext>13122618708</phone_ext>
      <email>wxdai17@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

